You are here:

rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)

Advice

Following a resubmission.

Rotigotine (Neupro®) is accepted for use within NHS Scotland for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa).

Rotigotine was superior to placebo in two randomised controlled trials. However, in one active comparator study it was less effective than a non-ergolinic dopamine agonist comparator. Rotigotine transdermal patch offers an alternative non-ergolinic dopamine agonist at a lower cost in a formulation that does not have to be taken by mouth.

Drug Details

Drug Name: rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro)
SMC Drug ID: 289/06
Manufacturer: Schwarz Pharma Ltd
Indication: Early-stage Parkinson's disease
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 9 July 2007

Archived Advice

Full submission 7 August 2006

Back